China Biopharmaceutical Regulatory Affairs Market Size & Outlook
China biopharmaceutical regulatory affairs market, 2018-2030 (US$M)
Related Markets
China biopharmaceutical regulatory affairs market highlights
- The China biopharmaceutical regulatory affairs market generated a revenue of USD 385.2 million in 2023 and is expected to reach USD 698.4 million by 2030.
- The China market is expected to grow at a CAGR of 8.9% from 2024 to 2030.
- In terms of segment, regulatory writing & publishing was the largest revenue generating services in 2023.
- Legal Representation is the most lucrative services segment registering the fastest growth during the forecast period.
Biopharmaceutical regulatory affairs market data book summary
| Market revenue in 2023 | USD 385.2 million |
| Market revenue in 2030 | USD 698.4 million |
| Growth rate | 8.9% (CAGR from 2023 to 2030) |
| Largest segment | Regulatory writing & publishing |
| Fastest growing segment | Legal Representation |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Regulatory Consulting, Legal Representation, Regulatory Writing & Publishing, Product Registration & Clinical Trial Applications, Other Services |
| Key market players worldwide | Genpact Ltd, Icon PLC, Promedica International, Wuxi AppTec Co Ltd, Medpace Holdings Inc, Charles River Laboratories International Inc, Labcorp Drug Development, Cencora Inc, Pharmexon, QVigilance, Voisin Consulting Life Sciences, Accell, Criterium Inc., Freyr Solutions, PharmaLex, NDA Regulatory Service GmbH, BlueReg Group, Cambridge Regulatory Services |
Other key industry trends
- In terms of revenue, China accounted for 10.2% of the global biopharmaceutical regulatory affairs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan biopharmaceutical regulatory affairs market is projected to lead the regional market in terms of revenue in 2030.
- India is the fastest growing regional market in Asia Pacific and is projected to reach USD 530.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biopharmaceutical Regulatory Affairs Market Scope
Biopharmaceutical Regulatory Affairs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
China biopharmaceutical regulatory affairs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biopharmaceutical regulatory affairs market will help companies and investors design strategic landscapes.
Regulatory writing & publishing was the largest segment with a revenue share of 31.49% in 2023. Horizon Databook has segmented the China biopharmaceutical regulatory affairs market based on regulatory consulting, legal representation, regulatory writing & publishing, product registration & clinical trial applications, other services covering the revenue growth of each sub-segment from 2018 to 2030.
China is one of the most attractive markets for the biopharmaceutical industry. The growing geriatric population and a large pool of middle-income group population are increasing the demand for innovative and cost-effective medicines, which is expected to attract major biopharmaceutical and medical device companies.
Seeking approval for new drugs is a primary challenge faced by biopharmaceutical companies, as a clinical trial application process requires 12 to 24 months. In contrast, approval process may require more than 6 years.
Along with national approvals, the new drug requires approval at the provincial and/or city level, which may require additional 4 to 5 years. Reforms in the healthcare sector in recent times are expected to streamline the approval process.
Reasons to subscribe to China biopharmaceutical regulatory affairs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China biopharmaceutical regulatory affairs market databook
-
Our clientele includes a mix of biopharmaceutical regulatory affairs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China biopharmaceutical regulatory affairs market , including forecasts for subscribers. This country databook contains high-level insights into China biopharmaceutical regulatory affairs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
China biopharmaceutical regulatory affairs market size, by services, 2018-2030 (US$M)
China Biopharmaceutical Regulatory Affairs Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
